Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094366931> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W2094366931 endingPage "30" @default.
- W2094366931 startingPage "22" @default.
- W2094366931 abstract "To evaluate the efficacy and safety of aripiprazole versus placebo in preventing relapse of irritability symptoms associated with autistic disorder in pediatric patients.This multicenter, double-blind, randomized, placebo-controlled, relapse-prevention trial enrolled patients (6-17 years) who met the current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DMS-IV-TR) criteria for autistic disorder and who also had serious behavioral problems (ie, tantrums, aggression, self-injurious behavior, or a combination of these behavioral problems) between March 2011 and June 2012. In phase 1, single-blind aripiprazole was flexibly dosed (2-15 mg/d) for 13-26 weeks. Patients with a stable response (≥ 25% decrease in Aberrant Behavior Checklist-irritability subscale score and a rating of much improved or very much improved on the Clinical Global Impressions-Improvement scale) for 12 consecutive weeks were randomized into phase 2 to continue aripiprazole or switch to placebo. Treatment was continued until relapse or up to 16 weeks. The primary end point was time from randomization to relapse.Eighty-five patients were randomized in phase 2. The difference in time to relapse between aripiprazole and placebo was not statistically significant (P = .097). Kaplan-Meier relapse rates at week 16 were 35% for aripiprazole and 52% for placebo (hazard ratio [HR] = 0.57; number needed to treat [NNT] = 6). The most common adverse events during phase 1 were weight increase (25.2%), somnolence (14.8%), and vomiting (14.2%); and, during phase 2 (aripiprazole vs placebo), they were upper respiratory tract infection (10.3% vs 2.3%), constipation (5.1% vs 0%), and movement disorder (5.1% vs 0%).In this study, there was no statistically significant difference between aripiprazole and placebo in time to relapse during maintenance therapy. However, the HR and NNT suggest some patients will benefit from maintenance treatment. Patients receiving aripiprazole should be periodically reassessed to determine the continued need for treatment.ClinicalTrials.gov identifier: NCT01227668." @default.
- W2094366931 created "2016-06-24" @default.
- W2094366931 creator A5000677832 @default.
- W2094366931 creator A5011817318 @default.
- W2094366931 creator A5024194700 @default.
- W2094366931 creator A5029547645 @default.
- W2094366931 creator A5036810356 @default.
- W2094366931 creator A5039951561 @default.
- W2094366931 creator A5042787535 @default.
- W2094366931 creator A5056126546 @default.
- W2094366931 creator A5059548352 @default.
- W2094366931 creator A5071579100 @default.
- W2094366931 date "2014-01-15" @default.
- W2094366931 modified "2023-09-26" @default.
- W2094366931 title "A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder" @default.
- W2094366931 doi "https://doi.org/10.4088/jcp.13m08500" @default.
- W2094366931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24502859" @default.
- W2094366931 hasPublicationYear "2014" @default.
- W2094366931 type Work @default.
- W2094366931 sameAs 2094366931 @default.
- W2094366931 citedByCount "81" @default.
- W2094366931 countsByYear W20943669312014 @default.
- W2094366931 countsByYear W20943669312015 @default.
- W2094366931 countsByYear W20943669312016 @default.
- W2094366931 countsByYear W20943669312017 @default.
- W2094366931 countsByYear W20943669312018 @default.
- W2094366931 countsByYear W20943669312019 @default.
- W2094366931 countsByYear W20943669312020 @default.
- W2094366931 countsByYear W20943669312021 @default.
- W2094366931 countsByYear W20943669312022 @default.
- W2094366931 countsByYear W20943669312023 @default.
- W2094366931 crossrefType "journal-article" @default.
- W2094366931 hasAuthorship W2094366931A5000677832 @default.
- W2094366931 hasAuthorship W2094366931A5011817318 @default.
- W2094366931 hasAuthorship W2094366931A5024194700 @default.
- W2094366931 hasAuthorship W2094366931A5029547645 @default.
- W2094366931 hasAuthorship W2094366931A5036810356 @default.
- W2094366931 hasAuthorship W2094366931A5039951561 @default.
- W2094366931 hasAuthorship W2094366931A5042787535 @default.
- W2094366931 hasAuthorship W2094366931A5056126546 @default.
- W2094366931 hasAuthorship W2094366931A5059548352 @default.
- W2094366931 hasAuthorship W2094366931A5071579100 @default.
- W2094366931 hasConcept C118552586 @default.
- W2094366931 hasConcept C126322002 @default.
- W2094366931 hasConcept C142724271 @default.
- W2094366931 hasConcept C15744967 @default.
- W2094366931 hasConcept C168563851 @default.
- W2094366931 hasConcept C187212893 @default.
- W2094366931 hasConcept C197934379 @default.
- W2094366931 hasConcept C204787440 @default.
- W2094366931 hasConcept C27081682 @default.
- W2094366931 hasConcept C2776412080 @default.
- W2094366931 hasConcept C2779034229 @default.
- W2094366931 hasConcept C2780211496 @default.
- W2094366931 hasConcept C2780820931 @default.
- W2094366931 hasConcept C558461103 @default.
- W2094366931 hasConcept C71924100 @default.
- W2094366931 hasConceptScore W2094366931C118552586 @default.
- W2094366931 hasConceptScore W2094366931C126322002 @default.
- W2094366931 hasConceptScore W2094366931C142724271 @default.
- W2094366931 hasConceptScore W2094366931C15744967 @default.
- W2094366931 hasConceptScore W2094366931C168563851 @default.
- W2094366931 hasConceptScore W2094366931C187212893 @default.
- W2094366931 hasConceptScore W2094366931C197934379 @default.
- W2094366931 hasConceptScore W2094366931C204787440 @default.
- W2094366931 hasConceptScore W2094366931C27081682 @default.
- W2094366931 hasConceptScore W2094366931C2776412080 @default.
- W2094366931 hasConceptScore W2094366931C2779034229 @default.
- W2094366931 hasConceptScore W2094366931C2780211496 @default.
- W2094366931 hasConceptScore W2094366931C2780820931 @default.
- W2094366931 hasConceptScore W2094366931C558461103 @default.
- W2094366931 hasConceptScore W2094366931C71924100 @default.
- W2094366931 hasIssue "01" @default.
- W2094366931 hasLocation W20943669311 @default.
- W2094366931 hasLocation W20943669312 @default.
- W2094366931 hasOpenAccess W2094366931 @default.
- W2094366931 hasPrimaryLocation W20943669311 @default.
- W2094366931 hasRelatedWork W1997443895 @default.
- W2094366931 hasRelatedWork W1999630630 @default.
- W2094366931 hasRelatedWork W2024097777 @default.
- W2094366931 hasRelatedWork W2029818273 @default.
- W2094366931 hasRelatedWork W2061864344 @default.
- W2094366931 hasRelatedWork W2094366931 @default.
- W2094366931 hasRelatedWork W2209305649 @default.
- W2094366931 hasRelatedWork W2758467604 @default.
- W2094366931 hasRelatedWork W2786883060 @default.
- W2094366931 hasRelatedWork W2958135184 @default.
- W2094366931 hasVolume "75" @default.
- W2094366931 isParatext "false" @default.
- W2094366931 isRetracted "false" @default.
- W2094366931 magId "2094366931" @default.
- W2094366931 workType "article" @default.